Engineered NK92 cell-derived exosomes inhibit ovarian cancer progression by degrading GPRC5A
Overall, this study provides a novel strategy to treat ovarian cancer through the preparation of genetically modified NK92 cell-derived exosomes loaded with RNA interference.
Authors
- Chaohua Si
- Xu Ma (ORCID: https://orcid.org/0000-0001-7674-3589)
- Jianen Gao (ORCID: https://orcid.org/0000-0001-7808-3254)
- Yunwen Wang (ORCID: https://orcid.org/0009-0006-6803-0777)
- Yuxuan Fan (ORCID: https://orcid.org/0000-0003-3707-8883)
- Yihan Wang (ORCID: https://orcid.org/0009-0008-6206-5738)
- Yuanyuan Li (ORCID: https://orcid.org/0000-0002-0320-5664)
- Yuqi Chen (ORCID: https://orcid.org/0000-0001-8605-7961)
- Yanan Tian (ORCID: https://orcid.org/0009-0002-6791-5005)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Genetic Resources Center (JP)
- China National Petroleum and Chemical Planning Institute (CN)
- Tianjin Municipal Research Institute for Family Planning (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.3389/fimmu.2025.1613178
- Citations
- 1
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.81